12:00 AM
 | 
Apr 03, 2000
 |  BC Week In Review  |  Company News  |  Deals

Karo Bio, Novalon deal

Karo, which is developing nuclear receptor-targeted therapeutics using structure-based drug design, will acquire Novalon in a stock transaction. Novalon is developing...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >